Smith & Nephew plc (LON:SN) Stock Has Consensus Target Price of GBX 1,293.33 According to Brokerages

Smith & Nephew plc (LON:SN) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is GBX 1,293.33.

SN has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price target on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a report on Thursday, August 6th. Royal Bank Of Canada decreased their target price on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,250 price objective on shares of Smith & Nephew in a research note on Tuesday, September 15th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,500 price target on shares of Smith & Nephew in a research report on Friday, September 4th. Finally, Berenberg Bank dropped their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research note on Friday, August 14th.

Smith & Nephew Stock Performance

Shares of SN stock opened at GBX 1,088 on Friday. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The business has a fifty day simple moving average of GBX 1,048.44 and a 200 day simple moving average of GBX 1,115.84. The company has a market capitalization of £11.93 billion, a P/E ratio of 39.17, a P/E/G ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.